About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Study on the Efficacy and Safety of IPyC for HER2+ MBC

NCT06990347·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Fujian Medical University

Age

18–70

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

patients who underwent a biopsy of the metastatic site and were confirmed as having MBC
patients who received inetetamab + pyrotinib + chemotherapy as metastasis therapy.

You may not be if

male patients or individuals with prior malignancy
patients with prior or current enrollment in interventional clinical trials for MBC
patients who received less than 2 cycles of treatment (6 weeks of inetetamab or 8 weeks of pyrotinib)
patients who were lost to follow-up during the therapeutic process

The record

StatusCompleted

PhaseNo phase

Taking part301

StartedJul 2020

UpdatedMay 25, 2025

Conditions

Where1

Fujian Cancer Hospital
Fuzhou, China

Clareo Health | A Study on the Efficacy and Safety of IPyC for HER2+ MBC